June 16, 2020
Oxford, UK, BURLINGTON, Mass., June 16, 2020 – Blue Earth Diagnostics, a Bracco company focused…
May 18, 2020
− Results related to Company’s investigational Phase 3 radiohybrid PSMA agent presented at the AUA2020…
May 1, 2020
Oxford, UK and BURLINGTON, Mass., May 1, 2020 – Blue Earth Diagnostics, a Bracco company focused…
April 21, 2020
Oxford, UK – April 21, 2020 – Blue Earth Diagnostics Ltd, a Bracco company focused on molecular…
March 17, 2020
− Rapid development of research program on investigational Prostate Specific Membrane Antigen-targeted radiohybrid PET imaging…
February 12, 2020
− ASCO 2020 Genitourinary Cancers Symposium and Radiation Oncology Summit: ACRO 2020 − BURLINGTON, Mass.…
September 16, 2019
− Results presented at ASTRO Annual Meeting evaluate clinical utility of 18F-fluciclovine PET/CT imaging in…
September 16, 2019
− Results presented at ASTRO Annual Meeting evaluate clinical utility of 18F-fluciclovine PET/CT imaging in men…
September 10, 2019
BURLINGTON, Mass. and OXFORD, UK, September 10, 2019 – Blue Earth Diagnostics, a Bracco company…
August 1, 2019
Oxford (UK), August 1st, 2019 - Bracco Imaging today announced that it has completed the…
June 27, 2019
‒ Blue Earth Diagnostics to become a subsidiary of Bracco Imaging; retains name and management…
June 27, 2019
- Results with investigational radiohybrid PSMA-targeted compound presented at SNMMI - BURLINGTON, Mass. and OXFORD,…
